Advertisement

Acta Diabetologica

, Volume 56, Issue 1, pp 67–71 | Cite as

Impact of ranibizumab on visual impairment in patients with bilateral diabetic macular edema

  • Franck Fajnkuchen
  • Dante Pieramici
  • Linda Hrarat
  • Anne-Laurence Best
  • Salomon Y. Cohen
  • Corinne Delahaye-Mazza
  • Typhaine Grenet
  • Sylvia Nghiem-Buffet
  • Gabriel Quentel
  • Bahram Bodaghi
  • Audrey Giocanti-AuréganEmail author
Original Article

Abstract

Aims

Diabetic macular edema (DME) frequently presents bilaterally. In case of bilateral retinal disease, the visual impairment (VI) and the visual acuity (VA) are strongly correlated to the better eye. The aim of this study was to assess the impact of ranibizumab intravitreal injections (IVR) on VI in patients with simultaneous VA loss due to DME.

Methods

This was a retrospective two-center study including consecutive DME patients with visual loss treated with ranibizumab since November 2011 and with a minimum follow-up of 6 months. Patients with bilateral visual decrease from DME undergoing IVR within 6 months of each other were included.

Results

Twenty-nine DME patients who received bilateral IVR within a 6-month interval in the second eye were included. At baseline, 82.8% (n = 24) of patients had a VA < 20/40 in their better eye versus 44.8% (n = 13) of patients at the end of follow-up, i.e. a reduction by 45.9% of VI. In the better eye, the mean VA was 57.3, 65.0 and 65.5 ETDRS letters, respectively, at baseline, month 3 and month 6 (mean VA gain +8.2 letters). In the worse eye, the mean VA was 44.2, 53.5 and 53.8 ETDRS letters, respectively, at baseline, M3 and M6 (mean VA gain +9.6 letters).

Conclusions

In patients with bilateral DME, subsequent ranibizumab IVR reduced VI frequency.

Keywords

Bilateral diabetic macular edema Anti-VEGF Disability Visual impairment 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Franck Fajnkuchen, Dr. Sylvia Nghiem-Buffet, and Dr. Audrey Giocanti-Aurégan report having received personal fees from Novartis, Bayer, Allergan, outside the scope of the submitted work. Dr. Dante Pieramici is consultant for Genentech, Regeneron, Thrombogenics, Novartis, and reports having received research Genentech, Regeneron, Ophthea, Regenerative Patch, RegenX Bio, Clearside Biomedical. Dr. Typhaine Grenet reports having received personal fees from Novartis, Bayer, outside the scope of the submitted work. Dr. Linda Hrarat, Dr. Anne-Laurence Best, Dr. Corinne Delahaye-Mazza and Prof. Bodaghi have nothing to disclose. Dr. Gabriel Quentel reports having received personal fees from Novartis outside the scope of the submitted work. Prof. Salomon Y. Cohen reports having received personal fees from Novartis, Bayer, Allergan, Alcon, Thea, outside the scope of the submitted work.

Ethical approval

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Yau JWY, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564CrossRefGoogle Scholar
  2. 2.
    Dervenis N, Mikropoulou AM, Tranos P, Dervenis P (2017) Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges. Adv Ther 34:1270–1282CrossRefGoogle Scholar
  3. 3.
    (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology 98:766–785Google Scholar
  4. 4.
    Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022CrossRefGoogle Scholar
  5. 5.
    Heier JS, Korobelnik J-F, Brown DM et al (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123:2376–2385CrossRefGoogle Scholar
  6. 6.
    Menchini U, Bandello F, De Angelis V et al (2015) Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study). J Ophthalmol 2015:324841Google Scholar
  7. 7.
    Patrao NV, Antao S, Egan C et al (2016) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service Setting. Am J Ophthalmol 172:51–57CrossRefGoogle Scholar
  8. 8.
    Hrarat L, Fajnkuchen F, Boubaya M et al (2016) Outcomes after a 1-year treatment with ranibizumab for diabetic macular edema in a clinical setting. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd 236:207–214Google Scholar
  9. 9.
    Stefanickova J, Cunha-Vaz J, Ulbig M et al (2018) A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmol (Copenh).  https://doi.org/10.1111/aos.13771 Google Scholar
  10. 10.
    Lamoureux EL, Hassell JB, Keeffe JE (2004) The impact of diabetic retinopathy on participation in daily living. Arch Ophthalmol 122:84–88CrossRefGoogle Scholar
  11. 11.
    (2018) Vision 2020 Global initiative for the elimination of avoidable blindness: action plan 2006–2011. http://www.who.int/mediacentre/factsheets/fs213/en/
  12. 12.
    Colenbrander A, De Laey JA (2006) Vision requirements for driving safety. Report of the International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/visionfordriving.pdf
  13. 13.
    Varma R, Bressler NM, Doan QV et al (2015) Visual Impairment and blindness avoided with ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States. Ophthalmology 122:982–989CrossRefGoogle Scholar
  14. 14.
    Mitchell P, Annemans L, Gallagher M et al (2012) Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 96:688–693CrossRefGoogle Scholar
  15. 15.
    Ou WC, Brown DM, Payne JF, Wykoff CC (2017) Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol 180:8–17CrossRefGoogle Scholar
  16. 16.
    Elman MJ, Ayala A, Bressler NM et al (2015) Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122:375–381CrossRefGoogle Scholar
  17. 17.
    Man REK, Fenwick EK, Sabanayagam C et al (2016) Differential impact of unilateral and bilateral classifications of diabetic retinopathy and diabetic macular edema on vision-related quality of life. Invest Ophthalmol Vis Sci 57:4655–4660CrossRefGoogle Scholar
  18. 18.
    Daien V, Peres K, Villain M et al (2014) Visual acuity thresholds associated with activity limitations in the elderly. The pathologies oculaires Liées à l’Age study. Acta Ophthalmol (Copenh) 92:e500–e506CrossRefGoogle Scholar
  19. 19.
    Rubin GS, Muñoz B, Bandeen-Roche K, West SK (2000) Monocular versus binocular visual acuity as measures of vision impairment and predictors of visual disability. Invest Ophthalmol Vis Sci 41:3327–3334Google Scholar
  20. 20.
    Sophie R, Lu N, Campochiaro PA (2015) Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with Ranibizumab. Ophthalmology 122:1395–1401CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Franck Fajnkuchen
    • 1
    • 2
  • Dante Pieramici
    • 3
  • Linda Hrarat
    • 2
  • Anne-Laurence Best
    • 2
  • Salomon Y. Cohen
    • 1
    • 4
  • Corinne Delahaye-Mazza
    • 1
  • Typhaine Grenet
    • 1
    • 2
  • Sylvia Nghiem-Buffet
    • 1
    • 2
  • Gabriel Quentel
    • 1
  • Bahram Bodaghi
    • 2
    • 5
  • Audrey Giocanti-Aurégan
    • 2
    Email author
  1. 1.OphthalmologyCentre d’Imagerie et de LaserParisFrance
  2. 2.Ophthalmology DepartmentAvicenne HospitalBobignyFrance
  3. 3.Partner California Retina ConsultantsDirector California Retina Research FoundationSanta BarbaraUSA
  4. 4.Centre Hospitalier Intercommunal CréteilCréteilFrance
  5. 5.Ophthalmology DepartmentPitié Salpétrière HospitalParisFrance

Personalised recommendations